Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial

Asaf Biber, Michal Mandelboim, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Eli Schwartz
doi: https://doi.org/10.1101/2021.05.31.21258081

Article Information

doi 
https://doi.org/10.1101/2021.05.31.21258081
History 
  • May 31, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Asaf Biber1,2,
  2. Michal Mandelboim2,3,
  3. Geva Harmelin4,
  4. Dana Lev1,2,
  5. Li Ram4,
  6. Amit Shaham4,
  7. Ital Nemet3,
  8. Limor Kliker3,
  9. Oran Erster3 and
  10. Eli Schwartz1,2,*
  1. 1The Center for Geographic Medicine and Tropical Diseases, Sheba Medical Center, Ramat Gan, Israel
  2. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  3. 3Central Virology Laboratory, Ministry of Health, Ramat Gan, Israel
  4. 4Emergency Medicine, Sheba Medical Center, Ramat Gan, Israel
  1. ↵*Corresponding author: Prof. Eli Schwartz MD, DTMH
    , The Center for Geographic Medicine and Tropical Diseases, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel, Tel/Fax:+ 972-3-5308456 Email: elischwa{at}tauex.tau.ac.il
Back to top
Posted May 31, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Asaf Biber, Michal Mandelboim, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Eli Schwartz
medRxiv 2021.05.31.21258081; doi: https://doi.org/10.1101/2021.05.31.21258081
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area